Trial Profile
A Phase 1/2 Study of Osimertinib in Combination With Gefitinib in EGFR Inhibitor naive Advanced EGFR Mutant Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 15 May 2023
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 May 2023 Planned End Date changed from 1 Apr 2024 to 1 Apr 2025.
- 09 May 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Apr 2024.
- 02 May 2022 Planned End Date changed from 1 Apr 2023 to 1 Apr 2024.